SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J. & CHICAGO--(BUSINESS WIRE)--Kardiga n, a heart health company modernizing cardiovascular (CV) drug development, announced today that it has acquired ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Semaglutide 2.4 mg was shown to reduce risk for major ...

Please provide your email address to receive an email when new articles are posted on . Danish registry data show 31% of people with obesity and a first MI met SELECT trial criteria and are eligible ...

VENICE, Italy — Four-year data from the SELECT cardiovascular outcomes trial show that the anti-obesity drug semaglutide (Wegovy) leads to clinically significant and durable weight loss, as well as ...

Data expected this summer evaluating a potential cardiovascular risk reduction from Novo Nordisk's (NVO) obesity drug Wegovy (semaglutide) could benefit both the Danish pharma and Eli Lilly (NYSE:LLY) ...

LAS VEGAS--(BUSINESS WIRE)--Wejo Group Limited (NASDAQ: WEJO), a global leader in cloud and software analytics generated from AV, EV and connected vehicle data (CVD), today announced it is developing ...

In today’s competitive job market, having a CV that stands out is crucial, especially for senior professionals aiming to secure leadership roles. While content is key, how that content is presented ...

Finerenone reduced the incidence of the primary composite endpoint of CV death, nonfatal MI, nonfatal stroke or hospitalization for heart failure by 13%. The prescribing information for Kerendia ® ...

Pregnant women with COVID-19 are at increased risk of severe disease, ICU stays, and adverse pregnancy and child-health outcomes, with the greatest risks in the unvaccinated population, a new state-of ...